𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer

✍ Scribed by Millward, MJ; Cantwell, BMJ; Dowsett, M; Carmichael, J; Harris, AL

Book ID
109836569
Publisher
Nature Publishing Group
Year
1991
Tongue
English
Weight
395 KB
Volume
63
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II study of peptichemio in advan
A phase II study of peptichemio in advanced breast cancer
✍ V. Hug; G. N. Hortobagyi; A. U. Buzdar; G. R. Blumenschein; W. Grose; M. A. Burg πŸ“‚ Article πŸ“… 1980 πŸ› John Wiley and Sons 🌐 English βš– 445 KB πŸ‘ 3 views
A phase I/II investigation of trioxifene
A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects
✍ Robert S. Witte; Brian Pruitt; Douglass C. Tormey; Scot Moss; David P. Rose; Pau πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 586 KB

Tamoxifen and trioxifene are antiestrogens that appear to have different endocrine effects when tested in rats. Whereas tamoxifen has considerable clinical activity, trioxifene is a new antiestrogen with undefined clinical activity. Thirty-six patients were treated with graded doses of trioxifene. T

A phase II study of combined 5-fluoroura
A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer
✍ Willy Mattsson; Finn Von Eyben; Lennart Hallsten; GΓΆran Bjelkengren πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 340 KB πŸ‘ 2 views

In a Phase I1 study, 50 patients with advanced breast cancer were treated with a combination of 5fluorouracil(lOO0 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen). The courses were repeated every third to sixth week. Although 35 patients had previously received combination c